Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinoma

Schmid, Hans-Peter; Morant, Rudolf; Bernhard, Jürg; Maibach, Rudolf; Swiss Group for Clinical Cancer Research, (SAKK) (2003). Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinoma. European urology, 43(1), pp. 28-30. Amsterdam: Elsevier 10.1016/S0302-2838(02)00539-0

[img] Text
1-s2.0-S0302283802005390-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (111kB)

In hormone refractory prostatic carcinoma (HRPCa), the majority of patients have bone metastases only, which are by definition non-measurable. This makes objective evaluation of chemotherapeutic agents difficult. Prostate specific antigen (PSA) as a dynamic model was analyzed as potential auxiliary end point in HRPCa.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Bernhard, Jürg Theodor

ISSN:

0302-2838

Publisher:

Elsevier

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:24

Last Modified:

24 Jul 2023 16:09

Publisher DOI:

10.1016/S0302-2838(02)00539-0

PubMed ID:

12507540

Web of Science ID:

000180876000005

BORIS DOI:

10.48350/37818

URI:

https://boris.unibe.ch/id/eprint/37818 (FactScience: 211451)

Actions (login required)

Edit item Edit item
Provide Feedback